Oncology Biosimilars Market Report

Global Oncology Biosimilars Market Study Report 2022 Historical Trends, Growth, and Forecast to 2028

  • POSTDATE：Mar 02, 2022
  • PAGES：231
  • REPORT CODE：GMM789161
  • REPORT SUMMARY
  • TABLE OF CONTENTS

  • Oncology Biosimilars market report explains the definition, types, applications, major countries, and major players of the Oncology Biosimilars market. The report mainly contains different types, applications, and regional historical data from 2017-2021 and forecast data from 2022-2028.

    The report contains qualitative and quantitative analysis of the entire industry.

    The influence of COVID-19 has been considered in the report. Coronavirus Impact is included in Chapter 2. In addition, Strategic Analytics to Boost Productivity and Profitability is included in Chapter 3.

    By Player:

    • BIOCAD

    • Dr Reddy’s Laboratories

    • Apotex

    • STADA Arzneimittel AG

    • Teva Pharmaceutical Industries Ltd

    • Intas Pharmaceuticals

    • Biocon

    • Celltrion

    • Sandoz International

    • Pfizer

    By Type:

    • mAb

    • Immunomodulators

    • Hematopoietic Agents

    • G-CSF

    • Others

    By End-User:

    • Retail Pharmacies

    • Hospital Pharmacy

    • Online Pharmacy

    By Region:

    North America

    • United States

    • Canada

    • Mexico

    Europe

    • Germany

    • UK

    • Spain

    • France

    • Italy

    • Denmark

    • Finland

    • Norway

    • Sweden

    • Poland

    • Russia

    • Turkey

    Asia-Pacific

    • China

    • Japan

    • India

    • South Korea

    • Pakistan

    • Bangladesh

    • Indonesia

    • Thailand

    • Singapore

    • Malaysia

    • Philippines

    • Vietnam

    • Others

    South America

    • Brazil

    • Colombia

    • Chile

    • Argentina

    • Venezuela

    • Peru

    • Puerto Rico

    • Ecuador

    • Others

    GCC

    • Bahrain

    • Kuwait

    • Oman

    • Qatar

    • Saudi Arabia

    • United Arab Emirates

    Africa

    • Nigeria

    • South Africa

    • Egypt

    • Algeriat

    • Others

    Oceania

    • Australia

    • New Zealand

  • TABLE OF CONTENT

    1. Global Oncology Biosimilars Executive Summary

    • 1.1 Introduction

    • 1.2 Market Panorama, 2022

    2 Coronavirus Impact

    • 2.1 Oncology Biosimilars Outlook to 2028- Original Forecasts

    • 2.2 Oncology Biosimilars Outlook to 2028- COVID-19 Affected Forecasts

    • 2.3 Impact on Industry

    3 Strategic Analytics to Boost Productivity and Profitability

    • 3.1 Potential Market Drivers and Opportunities

    • 3.2 New Challenges and Strategies

    • 3.3 Short Term and Long Term Oncology Biosimilars Market Trends

    4 Key Inferences

    5 Market Overview

    • 5.1 Current Market Scenario

    • 5.2 Porter's Five Forces Analysis

      • 5.2.1 Bargaining Power of Suppliers

      • 5.2.2 Bargaining Power of Consumers

      • 5.2.3 Threat of New Entrants

      • 5.2.4 Threat of Substitute Product and Services

      • 5.2.5 Competitive Rivalry within the Industry

    6 Global Oncology Biosimilars Market- Recent Developments

    • 6.1 Oncology Biosimilars Market News and Developments

    • 6.2 Oncology Biosimilars Market Deals Landscape

    7 Oncology Biosimilars Raw Materials and Cost Structure Analysis

    • 7.1 Oncology Biosimilars Key Raw Materials

    • 7.2 Oncology Biosimilars Price Trend of Key Raw Materials

    • 7.3 Oncology Biosimilars Key Suppliers of Raw Materials

    • 7.4 Oncology Biosimilars Market Concentration Rate of Raw Materials

    • 7.5 Oncology Biosimilars Cost Structure Analysis

      • 7.5.1 Oncology Biosimilars Raw Materials Analysis

      • 7.5.2 Oncology Biosimilars Labor Cost Analysis

      • 7.5.3 Oncology Biosimilars Manufacturing Expenses Analysis

    8 Global Oncology Biosimilars Import and Export Analysis (Top 10 Countries)

    • 8.1 Global Oncology Biosimilars Import by Region (Top 10 Countries) (2017-2028)

    • 8.2 Global Oncology Biosimilars Export by Region (Top 10 Countries) (2017-2028)

    9 Global Oncology Biosimilars Market Outlook by Types and Applications to 2022

    • 9.1 Global Oncology Biosimilars Consumption and Growth Rate by Type (2017-2022)

      • 9.1.1 Global mAb Consumption and Growth Rate (2017-2022)

      • 9.1.2 Global Immunomodulators Consumption and Growth Rate (2017-2022)

      • 9.1.3 Global Hematopoietic Agents Consumption and Growth Rate (2017-2022)

      • 9.1.4 Global G-CSF Consumption and Growth Rate (2017-2022)

      • 9.1.5 Global Others Consumption and Growth Rate (2017-2022)

    • 9.2 Global Oncology Biosimilars Consumption and Growth Rate by Application (2017-2022)

      • 9.2.1 Global Retail Pharmacies Consumption and Growth Rate (2017-2022)

      • 9.2.2 Global Hospital Pharmacy Consumption and Growth Rate (2017-2022)

      • 9.2.3 Global Online Pharmacy Consumption and Growth Rate (2017-2022)

    10 Region and Country-wise Oncology Biosimilars Market Analysis and Outlook till 2022

    • 10.1 Global Oncology Biosimilars Consumption (2017-2022)

    • 10.2 North America Consumption Analysis

      • 10.2.1 United States Oncology Biosimilars Consumption (2017-2022)

      • 10.2.2 Canada Oncology Biosimilars Consumption (2017-2022)

      • 10.2.3 Mexico Oncology Biosimilars Consumption (2017-2022)

    • 10.3 Europe Consumption Analysis

      • 10.3.1 Germany Oncology Biosimilars Consumption (2017-2022)

      • 10.3.2 UK Oncology Biosimilars Consumption (2017-2022)

      • 10.3.3 Spain Oncology Biosimilars Consumption (2017-2022)

      • 10.3.4 Belgium Oncology Biosimilars Consumption (2017-2022)

      • 10.3.5 France Oncology Biosimilars Consumption (2017-2022)

      • 10.3.6 Italy Oncology Biosimilars Consumption (2017-2022)

      • 10.3.7 Denmark Oncology Biosimilars Consumption (2017-2022)

      • 10.3.8 Finland Oncology Biosimilars Consumption (2017-2022)

      • 10.3.9 Norway Oncology Biosimilars Consumption (2017-2022)

      • 10.3.10 Sweden Oncology Biosimilars Consumption (2017-2022)

      • 10.3.11 Poland Oncology Biosimilars Consumption (2017-2022)

      • 10.3.12 Russia Oncology Biosimilars Consumption (2017-2022)

      • 10.3.13 Turkey Oncology Biosimilars Consumption (2017-2022)

    • 10.4 APAC Consumption Analysis

      • 10.4.1 China Oncology Biosimilars Consumption (2017-2022)

      • 10.4.2 Japan Oncology Biosimilars Consumption (2017-2022)

      • 10.4.3 India Oncology Biosimilars Consumption (2017-2022)

      • 10.4.4 South Korea Oncology Biosimilars Consumption (2017-2022)

      • 10.4.5 Pakistan Oncology Biosimilars Consumption (2017-2022)

      • 10.4.6 Bangladesh Oncology Biosimilars Consumption (2017-2022)

      • 10.4.7 Indonesia Oncology Biosimilars Consumption (2017-2022)

      • 10.4.8 Thailand Oncology Biosimilars Consumption (2017-2022)

      • 10.4.9 Singapore Oncology Biosimilars Consumption (2017-2022)

      • 10.4.10 Malaysia Oncology Biosimilars Consumption (2017-2022)

      • 10.4.11 Philippines Oncology Biosimilars Consumption (2017-2022)

      • 10.4.12 Vietnam Oncology Biosimilars Consumption (2017-2022)

    • 10.5 South America Consumption Analysis

      • 10.5.1 Brazil Oncology Biosimilars Consumption (2017-2022)

      • 10.5.2 Colombia Oncology Biosimilars Consumption (2017-2022)

      • 10.5.3 Chile Oncology Biosimilars Consumption (2017-2022)

      • 10.5.4 Argentina Oncology Biosimilars Consumption (2017-2022)

      • 10.5.5 Venezuela Oncology Biosimilars Consumption (2017-2022)

      • 10.5.6 Peru Oncology Biosimilars Consumption (2017-2022)

      • 10.5.7 Puerto Rico Oncology Biosimilars Consumption (2017-2022)

      • 10.5.8 Ecuador Oncology Biosimilars Consumption (2017-2022)

    • 10.6 GCC Consumption Analysis

      • 10.6.1 Bahrain Oncology Biosimilars Consumption (2017-2022)

      • 10.6.2 Kuwait Oncology Biosimilars Consumption (2017-2022)

      • 10.6.3 Oman Oncology Biosimilars Consumption (2017-2022)

      • 10.6.4 Qatar Oncology Biosimilars Consumption (2017-2022)

      • 10.6.5 Saudi Arabia Oncology Biosimilars Consumption (2017-2022)

      • 10.6.6 United Arab Emirates Oncology Biosimilars Consumption (2017-2022)

    • 10.7 Africa Consumption Analysis

      • 10.7.1 Nigeria Oncology Biosimilars Consumption (2017-2022)

      • 10.7.2 South Africa Oncology Biosimilars Consumption (2017-2022)

      • 10.7.3 Egypt Oncology Biosimilars Consumption (2017-2022)

      • 10.7.4 Algeria Oncology Biosimilars Consumption (2017-2022)

    • 10.8 Oceania Consumption Analysis

      • 10.8.1 Australia Oncology Biosimilars Consumption (2017-2022)

      • 10.8.2 New Zealand Oncology Biosimilars Consumption (2017-2022)

    11 Global Oncology Biosimilars Competitive Analysis

    • 11.1 BIOCAD

      • 11.1.1 BIOCAD Company Details

      • 11.1.2 BIOCAD Oncology Biosimilars Sales, Price, Value and Gross Profit (2017-2022)

      • 11.1.3 BIOCAD Oncology Biosimilars Main Business and Markets Served

      • 11.1.4 BIOCAD Oncology Biosimilars Product Portfolio

      • 11.1.5 Recent Research and Development Strategies

    • 11.2 Dr Reddy’s Laboratories

      • 11.2.1 Dr Reddy’s Laboratories Company Details

      • 11.2.2 Dr Reddy’s Laboratories Oncology Biosimilars Sales, Price, Value and Gross Profit (2017-2022)

      • 11.2.3 Dr Reddy’s Laboratories Oncology Biosimilars Main Business and Markets Served

      • 11.2.4 Dr Reddy’s Laboratories Oncology Biosimilars Product Portfolio

      • 11.2.5 Recent Research and Development Strategies

    • 11.3 Apotex

      • 11.3.1 Apotex Company Details

      • 11.3.2 Apotex Oncology Biosimilars Sales, Price, Value and Gross Profit (2017-2022)

      • 11.3.3 Apotex Oncology Biosimilars Main Business and Markets Served

      • 11.3.4 Apotex Oncology Biosimilars Product Portfolio

      • 11.3.5 Recent Research and Development Strategies

    • 11.4 STADA Arzneimittel AG

      • 11.4.1 STADA Arzneimittel AG Company Details

      • 11.4.2 STADA Arzneimittel AG Oncology Biosimilars Sales, Price, Value and Gross Profit (2017-2022)

      • 11.4.3 STADA Arzneimittel AG Oncology Biosimilars Main Business and Markets Served

      • 11.4.4 STADA Arzneimittel AG Oncology Biosimilars Product Portfolio

      • 11.4.5 Recent Research and Development Strategies

    • 11.5 Teva Pharmaceutical Industries Ltd

      • 11.5.1 Teva Pharmaceutical Industries Ltd Company Details

      • 11.5.2 Teva Pharmaceutical Industries Ltd Oncology Biosimilars Sales, Price, Value and Gross Profit (2017-2022)

      • 11.5.3 Teva Pharmaceutical Industries Ltd Oncology Biosimilars Main Business and Markets Served

      • 11.5.4 Teva Pharmaceutical Industries Ltd Oncology Biosimilars Product Portfolio

      • 11.5.5 Recent Research and Development Strategies

    • 11.6 Intas Pharmaceuticals

      • 11.6.1 Intas Pharmaceuticals Company Details

      • 11.6.2 Intas Pharmaceuticals Oncology Biosimilars Sales, Price, Value and Gross Profit (2017-2022)

      • 11.6.3 Intas Pharmaceuticals Oncology Biosimilars Main Business and Markets Served

      • 11.6.4 Intas Pharmaceuticals Oncology Biosimilars Product Portfolio

      • 11.6.5 Recent Research and Development Strategies

    • 11.7 Biocon

      • 11.7.1 Biocon Company Details

      • 11.7.2 Biocon Oncology Biosimilars Sales, Price, Value and Gross Profit (2017-2022)

      • 11.7.3 Biocon Oncology Biosimilars Main Business and Markets Served

      • 11.7.4 Biocon Oncology Biosimilars Product Portfolio

      • 11.7.5 Recent Research and Development Strategies

    • 11.8 Celltrion

      • 11.8.1 Celltrion Company Details

      • 11.8.2 Celltrion Oncology Biosimilars Sales, Price, Value and Gross Profit (2017-2022)

      • 11.8.3 Celltrion Oncology Biosimilars Main Business and Markets Served

      • 11.8.4 Celltrion Oncology Biosimilars Product Portfolio

      • 11.8.5 Recent Research and Development Strategies

    • 11.9 Sandoz International

      • 11.9.1 Sandoz International Company Details

      • 11.9.2 Sandoz International Oncology Biosimilars Sales, Price, Value and Gross Profit (2017-2022)

      • 11.9.3 Sandoz International Oncology Biosimilars Main Business and Markets Served

      • 11.9.4 Sandoz International Oncology Biosimilars Product Portfolio

      • 11.9.5 Recent Research and Development Strategies

    • 11.10 Pfizer

      • 11.10.1 Pfizer Company Details

      • 11.10.2 Pfizer Oncology Biosimilars Sales, Price, Value and Gross Profit (2017-2022)

      • 11.10.3 Pfizer Oncology Biosimilars Main Business and Markets Served

      • 11.10.4 Pfizer Oncology Biosimilars Product Portfolio

      • 11.10.5 Recent Research and Development Strategies

    12 Global Oncology Biosimilars Market Outlook by Types and Applications to 2028

    • 12.1 Global Oncology Biosimilars Consumption Forecast and Growth Rate by Type (2022-2028)

      • 12.1.1 Global mAb Consumption Forecast and Growth Rate (2022-2028)

      • 12.1.2 Global Immunomodulators Consumption Forecast and Growth Rate (2022-2028)

      • 12.1.3 Global Hematopoietic Agents Consumption Forecast and Growth Rate (2022-2028)

      • 12.1.4 Global G-CSF Consumption Forecast and Growth Rate (2022-2028)

      • 12.1.5 Global Others Consumption Forecast and Growth Rate (2022-2028)

    • 12.2 Global Oncology Biosimilars Consumption Forecast and Growth Rate by Application (2022-2028)

      • 12.2.1 Global Retail Pharmacies Consumption Forecast and Growth Rate (2022-2028)

      • 12.2.2 Global Hospital Pharmacy Consumption Forecast and Growth Rate (2022-2028)

      • 12.2.3 Global Online Pharmacy Consumption Forecast and Growth Rate (2022-2028)

    13 Country-wise Oncology Biosimilars Market Analysis and Outlook to 2028

    • 13.1 Global Oncology Biosimilars Consumption Forecast (2022-2028)

    • 13.2 North America Consumption Analysis

      • 13.2.1 United States Oncology Biosimilars Consumption Forecast (2022-2028)

      • 13.2.2 Canada Oncology Biosimilars Consumption Forecast (2022-2028)

      • 13.2.3 Mexico Oncology Biosimilars Consumption Forecast (2022-2028)

    • 13.3 Europe Consumption Analysis

      • 13.3.1 Germany Oncology Biosimilars Consumption Forecast (2022-2028)

      • 13.3.2 UK Oncology Biosimilars Consumption Forecast (2022-2028)

      • 13.3.3 Spain Oncology Biosimilars Consumption Forecast (2022-2028)

      • 13.3.4 Belgium Oncology Biosimilars Consumption Forecast (2022-2028)

      • 13.3.5 France Oncology Biosimilars Consumption Forecast (2022-2028)

      • 13.3.6 Italy Oncology Biosimilars Consumption Forecast (2022-2028)

      • 13.3.7 Denmark Oncology Biosimilars Consumption Forecast (2022-2028)

      • 13.3.8 Finland Oncology Biosimilars Consumption Forecast (2022-2028)

      • 13.3.9 Norway Oncology Biosimilars Consumption Forecast (2022-2028)

      • 13.3.10 Sweden Oncology Biosimilars Consumption Forecast (2022-2028)

      • 13.3.11 Poland Oncology Biosimilars Consumption Forecast (2022-2028)

      • 13.3.12 Russia Oncology Biosimilars Consumption Forecast (2022-2028)

      • 13.3.13 Turkey Oncology Biosimilars Consumption Forecast (2022-2028)

    • 13.4 APAC Consumption Analysis

      • 13.4.1 China Oncology Biosimilars Consumption Forecast (2022-2028)

      • 13.4.2 Japan Oncology Biosimilars Consumption Forecast (2022-2028)

      • 13.4.3 India Oncology Biosimilars Consumption Forecast (2022-2028)

      • 13.4.4 South Korea Oncology Biosimilars Consumption Forecast (2022-2028)

      • 13.4.5 Pakistan Oncology Biosimilars Consumption Forecast (2022-2028)

      • 13.4.6 Bangladesh Oncology Biosimilars Consumption Forecast (2022-2028)

      • 13.4.7 Indonesia Oncology Biosimilars Consumption Forecast (2022-2028)

      • 13.4.8 Thailand Oncology Biosimilars Consumption Forecast (2022-2028)

      • 13.4.9 Singapore Oncology Biosimilars Consumption Forecast (2022-2028)

      • 13.4.10 Malaysia Oncology Biosimilars Consumption Forecast (2022-2028)

      • 13.4.11 Philippines Oncology Biosimilars Consumption Forecast (2022-2028)

      • 13.4.12 Vietnam Oncology Biosimilars Consumption Forecast (2022-2028)

    • 13.5 South America Consumption Analysis

      • 13.5.1 Brazil Oncology Biosimilars Consumption Forecast (2022-2028)

      • 13.5.2 Colombia Oncology Biosimilars Consumption Forecast (2022-2028)

      • 13.5.3 Chile Oncology Biosimilars Consumption Forecast (2022-2028)

      • 13.5.4 Argentina Oncology Biosimilars Consumption Forecast (2022-2028)

      • 13.5.5 Venezuela Oncology Biosimilars Consumption Forecast (2022-2028)

      • 13.5.6 Peru Oncology Biosimilars Consumption Forecast (2022-2028)

      • 13.5.7 Puerto Rico Oncology Biosimilars Consumption Forecast (2022-2028)

      • 13.5.8 Ecuador Oncology Biosimilars Consumption Forecast (2022-2028)

    • 13.6 GCC Consumption Analysis

      • 13.6.1 Bahrain Oncology Biosimilars Consumption Forecast (2022-2028)

      • 13.6.2 Kuwait Oncology Biosimilars Consumption Forecast (2022-2028)

      • 13.6.3 Oman Oncology Biosimilars Consumption Forecast (2022-2028)

      • 13.6.4 Qatar Oncology Biosimilars Consumption Forecast (2022-2028)

      • 13.6.5 Saudi Arabia Oncology Biosimilars Consumption Forecast (2022-2028)

      • 13.6.6 United Arab Emirates Oncology Biosimilars Consumption Forecast (2022-2028)

    • 13.7 Africa Consumption Analysis

      • 13.7.1 Nigeria Oncology Biosimilars Consumption Forecast (2022-2028)

      • 13.7.2 South Africa Oncology Biosimilars Consumption Forecast (2022-2028)

      • 13.7.3 Egypt Oncology Biosimilars Consumption Forecast (2022-2028)

      • 13.7.4 Algeria Oncology Biosimilars Consumption Forecast (2022-2028)

    • 13.8 Oceania Consumption Analysis

      • 13.8.1 Australia Oncology Biosimilars Consumption Forecast (2022-2028)

      • 13.8.2 New Zealand Oncology Biosimilars Consumption Forecast (2022-2028)

    14 Conclusions


    The List of Tables and Figures

    • Table Definition of Oncology Biosimilars

    • Figure of Oncology Biosimilars Picture

    • Table Global Oncology Biosimilars Import by Region (Top 10 Countries) (2017-2028)

    • Table Global Oncology Biosimilars Export by Region (Top 10 Countries) (2017-2028)

    • Figure Global mAb Consumption and Growth Rate (2017-2022)

    • Figure Global Immunomodulators Consumption and Growth Rate (2017-2022)

    • Figure Global Hematopoietic Agents Consumption and Growth Rate (2017-2022)

    • Figure Global G-CSF Consumption and Growth Rate (2017-2022)

    • Figure Global Others Consumption and Growth Rate (2017-2022)

    • Figure Global Retail Pharmacies Consumption and Growth Rate (2017-2022)

    • Figure Global Hospital Pharmacy Consumption and Growth Rate (2017-2022)

    • Figure Global Online Pharmacy Consumption and Growth Rate (2017-2022)

    • Figure Global Oncology Biosimilars Consumption by Country (2017-2022)

    • Table North America Oncology Biosimilars Consumption by Country (2017-2022)

    • Figure United States Oncology Biosimilars Consumption and Growth Rate (2017-2022)

    • Figure Canada Oncology Biosimilars Consumption and Growth Rate (2017-2022)

    • Figure Mexico Oncology Biosimilars Consumption and Growth Rate (2017-2022)

    • Table Europe Oncology Biosimilars Consumption by Country (2017-2022)

    • Figure Germany Oncology Biosimilars Consumption and Growth Rate (2017-2022)

    • Figure UK Oncology Biosimilars Consumption and Growth Rate (2017-2022)

    • Figure Spain Oncology Biosimilars Consumption and Growth Rate (2017-2022)

    • Figure Belgium Oncology Biosimilars Consumption and Growth Rate (2017-2022)

    • Figure France Oncology Biosimilars Consumption and Growth Rate (2017-2022)

    • Figure Italy Oncology Biosimilars Consumption and Growth Rate (2017-2022)

    • Figure Denmark Oncology Biosimilars Consumption and Growth Rate (2017-2022)

    • Figure Finland Oncology Biosimilars Consumption and Growth Rate (2017-2022)

    • Figure Norway Oncology Biosimilars Consumption and Growth Rate (2017-2022)

    • Figure Sweden Oncology Biosimilars Consumption and Growth Rate (2017-2022)

    • Figure Poland Oncology Biosimilars Consumption and Growth Rate (2017-2022)

    • Figure Russia Oncology Biosimilars Consumption and Growth Rate (2017-2022)

    • Figure Turkey Oncology Biosimilars Consumption and Growth Rate (2017-2022)

    • Table APAC Oncology Biosimilars Consumption by Country (2017-2022)

    • Figure China Oncology Biosimilars Consumption and Growth Rate (2017-2022)

    • Figure Japan Oncology Biosimilars Consumption and Growth Rate (2017-2022)

    • Figure India Oncology Biosimilars Consumption and Growth Rate (2017-2022)

    • Figure South Korea Oncology Biosimilars Consumption and Growth Rate (2017-2022)

    • Figure Pakistan Oncology Biosimilars Consumption and Growth Rate (2017-2022)

    • Figure Bangladesh Oncology Biosimilars Consumption and Growth Rate (2017-2022)

    • Figure Indonesia Oncology Biosimilars Consumption and Growth Rate (2017-2022)

    • Figure Thailand Oncology Biosimilars Consumption and Growth Rate (2017-2022)

    • Figure Singapore Oncology Biosimilars Consumption and Growth Rate (2017-2022)

    • Figure Malaysia Oncology Biosimilars Consumption and Growth Rate (2017-2022)

    • Figure Philippines Oncology Biosimilars Consumption and Growth Rate (2017-2022)

    • Figure Vietnam Oncology Biosimilars Consumption and Growth Rate (2017-2022)

    • Table South America Oncology Biosimilars Consumption by Country (2017-2022)

    • Figure Brazil Oncology Biosimilars Consumption and Growth Rate (2017-2022)

    • Figure Colombia Oncology Biosimilars Consumption and Growth Rate (2017-2022)

    • Figure Chile Oncology Biosimilars Consumption and Growth Rate (2017-2022)

    • Figure Argentina Oncology Biosimilars Consumption and Growth Rate (2017-2022)

    • Figure Venezuela Oncology Biosimilars Consumption and Growth Rate (2017-2022)

    • Figure Peru Oncology Biosimilars Consumption and Growth Rate (2017-2022)

    • Figure Puerto Rico Oncology Biosimilars Consumption and Growth Rate (2017-2022)

    • Figure Ecuador Oncology Biosimilars Consumption and Growth Rate (2017-2022)

    • Table GCC Oncology Biosimilars Consumption by Country (2017-2022)

    • Figure Bahrain Oncology Biosimilars Consumption and Growth Rate (2017-2022)

    • Figure Kuwait Oncology Biosimilars Consumption and Growth Rate (2017-2022)

    • Figure Oman Oncology Biosimilars Consumption and Growth Rate (2017-2022)

    • Figure Qatar Oncology Biosimilars Consumption and Growth Rate (2017-2022)

    • Figure Saudi Arabia Oncology Biosimilars Consumption and Growth Rate (2017-2022)

    • Figure United Arab Emirates Oncology Biosimilars Consumption and Growth Rate (2017-2022)

    • Table Africa Oncology Biosimilars Consumption by Country (2017-2022)

    • Figure Nigeria Oncology Biosimilars Consumption and Growth Rate (2017-2022)

    • Figure South Africa Oncology Biosimilars Consumption and Growth Rate (2017-2022)

    • Figure Egypt Oncology Biosimilars Consumption and Growth Rate (2017-2022)

    • Figure Algeria Oncology Biosimilars Consumption and Growth Rate (2017-2022)

    • Table Oceania Oncology Biosimilars Consumption by Country (2017-2022)

    • Figure Australia Oncology Biosimilars Consumption and Growth Rate (2017-2022)

    • Figure New Zealand Oncology Biosimilars Consumption and Growth Rate (2017-2022)

    • Table BIOCAD Company Details

    • Table BIOCAD Oncology Biosimilars Sales, Price, Value and Gross Profit (2017-2022)

    • Table BIOCAD Oncology Biosimilars Main Business and Markets Served

    • Table BIOCAD Oncology Biosimilars Product Portfolio

    • Table Dr Reddy’s Laboratories Company Details

    • Table Dr Reddy’s Laboratories Oncology Biosimilars Sales, Price, Value and Gross Profit (2017-2022)

    • Table Dr Reddy’s Laboratories Oncology Biosimilars Main Business and Markets Served

    • Table Dr Reddy’s Laboratories Oncology Biosimilars Product Portfolio

    • Table Apotex Company Details

    • Table Apotex Oncology Biosimilars Sales, Price, Value and Gross Profit (2017-2022)

    • Table Apotex Oncology Biosimilars Main Business and Markets Served

    • Table Apotex Oncology Biosimilars Product Portfolio

    • Table STADA Arzneimittel AG Company Details

    • Table STADA Arzneimittel AG Oncology Biosimilars Sales, Price, Value and Gross Profit (2017-2022)

    • Table STADA Arzneimittel AG Oncology Biosimilars Main Business and Markets Served

    • Table STADA Arzneimittel AG Oncology Biosimilars Product Portfolio

    • Table Teva Pharmaceutical Industries Ltd Company Details

    • Table Teva Pharmaceutical Industries Ltd Oncology Biosimilars Sales, Price, Value and Gross Profit (2017-2022)

    • Table Teva Pharmaceutical Industries Ltd Oncology Biosimilars Main Business and Markets Served

    • Table Teva Pharmaceutical Industries Ltd Oncology Biosimilars Product Portfolio

    • Table Intas Pharmaceuticals Company Details

    • Table Intas Pharmaceuticals Oncology Biosimilars Sales, Price, Value and Gross Profit (2017-2022)

    • Table Intas Pharmaceuticals Oncology Biosimilars Main Business and Markets Served

    • Table Intas Pharmaceuticals Oncology Biosimilars Product Portfolio

    • Table Biocon Company Details

    • Table Biocon Oncology Biosimilars Sales, Price, Value and Gross Profit (2017-2022)

    • Table Biocon Oncology Biosimilars Main Business and Markets Served

    • Table Biocon Oncology Biosimilars Product Portfolio

    • Table Celltrion Company Details

    • Table Celltrion Oncology Biosimilars Sales, Price, Value and Gross Profit (2017-2022)

    • Table Celltrion Oncology Biosimilars Main Business and Markets Served

    • Table Celltrion Oncology Biosimilars Product Portfolio

    • Table Sandoz International Company Details

    • Table Sandoz International Oncology Biosimilars Sales, Price, Value and Gross Profit (2017-2022)

    • Table Sandoz International Oncology Biosimilars Main Business and Markets Served

    • Table Sandoz International Oncology Biosimilars Product Portfolio

    • Table Pfizer Company Details

    • Table Pfizer Oncology Biosimilars Sales, Price, Value and Gross Profit (2017-2022)

    • Table Pfizer Oncology Biosimilars Main Business and Markets Served

    • Table Pfizer Oncology Biosimilars Product Portfolio

    • Figure Global mAb Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Immunomodulators Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Hematopoietic Agents Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global G-CSF Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Others Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Retail Pharmacies Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Hospital Pharmacy Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Online Pharmacy Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Oncology Biosimilars Consumption Forecast by Country (2022-2028)

    • Table North America Oncology Biosimilars Consumption Forecast by Country (2022-2028)

    • Figure United States Oncology Biosimilars Consumption Forecast and Growth Rate (2022-2028)

    • Figure Canada Oncology Biosimilars Consumption Forecast and Growth Rate (2022-2028)

    • Figure Mexico Oncology Biosimilars Consumption Forecast and Growth Rate (2022-2028)

    • Table Europe Oncology Biosimilars Consumption Forecast by Country (2022-2028)

    • Figure Germany Oncology Biosimilars Consumption Forecast and Growth Rate (2022-2028)

    • Figure UK Oncology Biosimilars Consumption Forecast and Growth Rate (2022-2028)

    • Figure Spain Oncology Biosimilars Consumption Forecast and Growth Rate (2022-2028)

    • Figure Belgium Oncology Biosimilars Consumption Forecast and Growth Rate (2022-2028)

    • Figure France Oncology Biosimilars Consumption Forecast and Growth Rate (2022-2028)

    • Figure Italy Oncology Biosimilars Consumption Forecast and Growth Rate (2022-2028)

    • Figure Denmark Oncology Biosimilars Consumption Forecast and Growth Rate (2022-2028)

    • Figure Finland Oncology Biosimilars Consumption Forecast and Growth Rate (2022-2028)

    • Figure Norway Oncology Biosimilars Consumption Forecast and Growth Rate (2022-2028)

    • Figure Sweden Oncology Biosimilars Consumption Forecast and Growth Rate (2022-2028)

    • Figure Poland Oncology Biosimilars Consumption Forecast and Growth Rate (2022-2028)

    • Figure Russia Oncology Biosimilars Consumption Forecast and Growth Rate (2022-2028)

    • Figure Turkey Oncology Biosimilars Consumption Forecast and Growth Rate (2022-2028)

    • Table APAC Oncology Biosimilars Consumption Forecast by Country (2022-2028)

    • Figure China Oncology Biosimilars Consumption Forecast and Growth Rate (2022-2028)

    • Figure Japan Oncology Biosimilars Consumption Forecast and Growth Rate (2022-2028)

    • Figure India Oncology Biosimilars Consumption Forecast and Growth Rate (2022-2028)

    • Figure South Korea Oncology Biosimilars Consumption Forecast and Growth Rate (2022-2028)

    • Figure Pakistan Oncology Biosimilars Consumption Forecast and Growth Rate (2022-2028)

    • Figure Bangladesh Oncology Biosimilars Consumption Forecast and Growth Rate (2022-2028)

    • Figure Indonesia Oncology Biosimilars Consumption Forecast and Growth Rate (2022-2028)

    • Figure Thailand Oncology Biosimilars Consumption Forecast and Growth Rate (2022-2028)

    • Figure Singapore Oncology Biosimilars Consumption Forecast and Growth Rate (2022-2028)

    • Figure Malaysia Oncology Biosimilars Consumption Forecast and Growth Rate (2022-2028)

    • Figure Philippines Oncology Biosimilars Consumption Forecast and Growth Rate (2022-2028)

    • Figure Vietnam Oncology Biosimilars Consumption Forecast and Growth Rate (2022-2028)

    • Table South America Oncology Biosimilars Consumption Forecast by Country (2022-2028)

    • Figure Brazil Oncology Biosimilars Consumption Forecast and Growth Rate (2022-2028)

    • Figure Colombia Oncology Biosimilars Consumption Forecast and Growth Rate (2022-2028)

    • Figure Chile Oncology Biosimilars Consumption Forecast and Growth Rate (2022-2028)

    • Figure Argentina Oncology Biosimilars Consumption Forecast and Growth Rate (2022-2028)

    • Figure Venezuela Oncology Biosimilars Consumption Forecast and Growth Rate (2022-2028)

    • Figure Peru Oncology Biosimilars Consumption Forecast and Growth Rate (2022-2028)

    • Figure Puerto Rico Oncology Biosimilars Consumption Forecast and Growth Rate (2022-2028)

    • Figure Ecuador Oncology Biosimilars Consumption Forecast and Growth Rate (2022-2028)

    • Table GCC Oncology Biosimilars Consumption Forecast by Country (2022-2028)

    • Figure Bahrain Oncology Biosimilars Consumption Forecast and Growth Rate (2022-2028)

    • Figure Kuwait Oncology Biosimilars Consumption Forecast and Growth Rate (2022-2028)

    • Figure Oman Oncology Biosimilars Consumption Forecast and Growth Rate (2022-2028)

    • Figure Qatar Oncology Biosimilars Consumption Forecast and Growth Rate (2022-2028)

    • Figure Saudi Arabia Oncology Biosimilars Consumption Forecast and Growth Rate (2022-2028)

    • Figure United Arab Emirates Oncology Biosimilars Consumption Forecast and Growth Rate (2022-2028)

    • Table Africa Oncology Biosimilars Consumption Forecast by Country (2022-2028)

    • Figure Nigeria Oncology Biosimilars Consumption Forecast and Growth Rate (2022-2028)

    • Figure South Africa Oncology Biosimilars Consumption Forecast and Growth Rate (2022-2028)

    • Figure Egypt Oncology Biosimilars Consumption Forecast and Growth Rate (2022-2028)

    • Figure Algeria Oncology Biosimilars Consumption Forecast and Growth Rate (2022-2028)

    • Table Oceania Oncology Biosimilars Consumption Forecast by Country (2022-2028)

    • Figure Australia Oncology Biosimilars Consumption Forecast and Growth Rate (2022-2028)

    • Figure New Zealand Oncology Biosimilars Consumption Forecast and Growth Rate (2022-2028)

Report Version Choose

Report

BUY NOW

Our Customers

Beyond grateful for the confidence and support from all partners and customers.A win-win situation is our ultimate pursuit.

Beyond Consulting, Future is Feasible

We provide more professional and intelligent market reports to complement your business decisions.

CONTACT US